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Abstract
Aim: The loss of insulin-secreting β-cells, ultimately characterizing most diabetes 
forms, demands the development of cell replacement therapies. The common end-
point for all ex vivo strategies is transplantation into diabetic patients. However, the 
effects of hyperglycaemia environment on the transplanted cells were not yet prop-
erly assessed. Thus, the main goal of this study was to characterize global effect of 
brief and prolonged in vivo hyperglycaemia exposure on the cell fate acquisition and 
maintenance of transplanted human pancreatic progenitors.
Methods: To rigorously study the effect of hyperglycaemia, in vitro differentiated 
human-induced pluripotent stem cells (hiPSC)-derived pancreatic progenitors were 
xenotransplanted in normoglycaemic and diabetic NSG rat insulin promoter (RIP)-
diphtheria toxin receptor (DTR) mice. The transplants were retrieved after 1-week or 
1-month exposure to overt hyperglycaemia and analysed by large-scale microscopy 
or global proteomics. For this study we pioneer the use of the NSG RIP-DTR system 
in the transplantation of hiPSC, making use of its highly reproducible specific and ab-
solute β-cell ablation property in the absence of inflammation or other organ toxicity.
Results: Here we show for the first time that besides the presence of an induced oxida-
tive stress signature, the cell fate and proteome landscape response to hyperglycaemia 
was different, involving largely different mechanisms, according to the period spent 
in the hyperglycaemic environment. Surprisingly, brief hyperglycaemia exposure in-
creased the bihormonal cell number by impeding the activity of specific islet lineage 
determinants. Moreover, it activated antioxidant and inflammation protection mecha-
nisms signatures in the transplanted cells. In contrast, the prolonged exposure was 
characterized by decreased numbers of hormone + cells, low/absent detoxification 
signature, augmented production of oxygen reactive species and increased apoptosis.
Conclusion: Hyperglycaemia exposure induced distinct, period-dependent, negative 
effects on xenotransplanted human pancreatic progenitor, affecting their energy ho-
meostasis, cell fate acquisition and survival.
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1 |  INTRODUCTION
Diabetes mellitus is a group of metabolic diseases charac-
terized by chronic increase in blood sugar levels (hypergly-
caemia) triggered by the inability of the body to produce or 
use sufficient insulin.1 Insulin is produced by the β-cells, 
which reside in the pancreatic islets together with other cell 
types secreting hormones involved in glucose homeostasis: 
the α-cells (glucagon), δ-cells (somatostatin), γ-cells (pan-
creatic polypeptide) and ε-cells (ghrelin). Most forms of di-
abetes are ultimately characterized by the loss of functional 
insulin-secreting β-cells, thus a stable cure will require their 
replacement.
Human-induced pluripotent stem cells (hiPSCs) can be 
differentiated towards insulin-producing cells by stepwise 
addition of factors mimicking pancreas development.2-4 The 
outcome of most current protocols is a heterogeneous popula-
tion comprising of cells expressing different islet hormones, 
including polyhormonal entities.5-7 In vivo transplantation 
of these cells at the last stages of guided differentiation im-
proves β-cell maturation,2,8 normalizing the glycaemia in di-
abetic mice.9-13
Although the above examples prove that transplanted 
cells are able to differentiate and function in hypergly-
caemic conditions, it remains an open question whether 
hyperglycaemia impedes or promotes the differentiation 
potential of the transplanted cells. To our knowledge, there 
are no rigorous studies addressing the in vivo impact of 
hyperglycaemia exposure on the transplanted cells differ-
entiation as compared to a normoglycaemic environment. 
Addressing this problem has both fundamental science and 
clinical implications.
2 |  RESULTS
2.1 | NSG rat insulin promoter-diphtheria 
toxin receptor as an ideal model system for the 
in vivo study of the hyperglycaemia effect on 
human islet cell differentiation
To investigate the in vivo impact of hyperglycaemia on islet 
cells differentiation, we xenotransplanted (TX) alginate-en-
capsulated hiPSC-derived pancreatic progenitor cells (here 
forth S5-cells) in either normal or diabetic humanized NSG 
rat insulin promoter (RIP)-diphtheria toxin receptor (DTR) 
mice (Figure 1A). For β-cell differentiation we used the pro-
tocol designed by Rezania et al9 with slight modifications 
as previously described.5,14 The encapsulated cells were 
exposed to either a brief (1 week, here on 1w-postTX) or an 
extended period of time (4 weeks, here on 4w-postTX) in the 
in vivo hyperglycaemic environment. These time points were 
selected to allow both the examination of the initial changes 
in the cells’ regulatory landscape, known to occur rapidly in 
response to altered cell signalling or environmental cues,15,16 
and the assessment of the long-term effect of hyperglycaemia 
on the cells.
To achieve highly reproducible hyperglycaemia condi-
tions, we employed the RIP-DTR genetic system, allow-
ing the rapid and specific ablation of the insulin-producing 
β-cells in vivo, in the absence of autoimmunity or inflam-
mation.17,18 In these mice, the DTR is specifically over-
expressed on the surface of the β-cells, under the control 
of the RIP. As previously described, upon diphtheria toxin 
(DT) administration, the β-cell compartment is specifi-
cally ablated with extremely high and reproducible effi-
ciency (97.88% in NSG RIP-DTR, Figure 1B,C), similar 
to the one reported for SCID RIP-DTR (97.8%).19 Ablated 
animals developed hyperglycaemia and displayed lower 
weight compared to their normoglycaemic counterparts 
(Figure 1D,E). In contrast to the available chemical mod-
els of β-cell ablation, DT does not affect other organs or 
systems because of the absent DTR expression in murine 
tissues, explaining the high animal survival rate following 
the transplant procedure (93.3%, 1/15).
Diabetic animals were xenotransplanted intraperitoneally 
with ~5  mil hiPSC-derived S5-cells (pancreatic progenitor 
stage), expressing typical markers of pancreatic progenitors 
(Figure S1A) obtained by guided in vitro differentiation, 
10  days following DT-administration (Figure 1A,D). The 
cells were encapsulated in alginate20 just before the trans-
plantation as alginate (a) allows easy sample recovery, (b) 
protects against the immune system attack and (c) promotes 
the islet cell differentiation potential probably through the 
mechanical forces elicited by encapsulation.21
Cell viability was over 94% (97.65%  ±  0.35 for 
1w-postTX and 95.5% ± 1.7 for 4w-postTX). Higher levels 
of human insulin were detected in the blood of the xeno-
transplanted hyperglycaemic mice as compared to normo-
glycaemic hosts, probably because of chronic high glucose 
stimulation (Figure S1B) and potentially contributing to the 
slight drop in glycaemia values observed following trans-
plant (Figure 1D). Capsules’ sizes remained unchanged in 
the beads recovered 1w- or 4w-postTX, regardless of the 
glycaemic status (Figure 1F,G). Following capsule retrieval, 
the encapsulated cells presented spheroidal morphology, 
typical of cells in suspension in all conditions analysed 
(Figures 1H and 2A).
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F I G U R E  1  Transplantation setup. (A) Experimental design (B) Confocal imaging of control and DT-ablated islet sections (insulin—red, 
glucagon—green, scale bar: 70 µm), (C) Efficiency of DT-induced β-cell ablation in RIP-DTR NSG strain expressed as % insulin cells/islet 
section. (D) Glycaemia and (E) Weight evolution in ablated and control mice (chartreuse—1w-posTX, blue—4w-postTX, TX—transplant, 
DT—DT-induced ablation, i—insulin implant), (F) Binocular imaging of the mounted alginate capsules and (G) 3D reconstructions of the 
immunofluorescence on whole alginate beads of the four conditions analysed of the 4 conditions analysed following the retrieval procedure 
(insulin—green, and DAPI—blue, scale bar: 200 µm) (H) High magnification confocal imaging of insulin+ cells (scale bar: 5 µm). Data are shown 
as mean ± SD. DT, diphtheria toxin; DTR, diphtheria toxin receptor; RIP, rat insulin promoter
4 of 16 |   LEGØY Et aL.
2.2 | Short in vivo exposure to 
hyperglycaemia increases the number of 
bihormonal glucagon+insulin+ cells
To assess the impact of hyperglycaemia on the differentiation 
outcome of the transplanted cells, we performed whole mount 
immunofluorescence staining on the retrieved capsules and 
quantified the numbers of hormone positive cells (Figure 2A). 
To allow a good coverage of the capsule volume, 9 fields of 
view (FoV) were acquired over 100 different focal planes, 
followed by 3D reconstruction and automatic quantification 
with manual supervision on Imaris 9.1.2.
Following the short in vivo exposure to hyperglycaemia, 
a slight increase was observed in the percentage of ins+-cells 
F I G U R E  2  Comparison of hormone expression in encapsulated transplanted cells retrieved from either normoglycaemic or diabetic mice. 
(A) High magnification confocal imaging of representative insulin+ (green), glucagon+ (red) and bihormonal cells (arrows) cells (scale bar: 5 µm). 
(B) Proportion of transplanted cells expressing insulin or glucagon in 1w_postTX conditions, (C) Fraction of insulin cells co-expressing glucagon 
(bihormonal cells) in 1w_postTX conditions, (D) Proportion of transplanted cells expressing NKX6.1, PDX1 or MAFA in 1w_postTX conditions. 
(E) Fraction of insulin+ cells co-expressing NKX6.1, PDX1 or MAFA in 1w-postTX conditions. (F) Proportion of transplanted cells expressing 
insulin or glucagon in 4w_postTX conditions, (G) Fraction of insulin cells co-expressing glucagon (bihormonal cells) and (H) Proportion of 
transplanted cells expressing NKX6.1, PDX1 or MAFA in 4w_postTX conditions,. (I) Fraction of insulin+ cells co-expressing NKX6.1, PDX1 or 
MAFA in 4w-postTX conditions. Data are shown as mean ± SD
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(~6%, 19.23%-25.47%) and, to a higher extent, glu+-cells 
(~13%, 9.84%-23.69%) as compared to normoglycaemic 
controls (Figure 2B). Nevertheless, most of these cells were 
bihormonal (10%, 6.31%-16.3%), co-expressing both insu-
lin and glucagon, suggestive of their immature or defective 
status (Figure 2A,B). Moreover, there was no significant in-
crease in the fraction of cells expressing PDX1, NKX6.1 or 
MAFA, three vital β-cell markers, neither in the total trans-
planted cell population (Figure 2D), nor in the insulin+ cell 
subpopulation (Figure 2E).
These data suggest that despite apparently incrementing 
the numbers of hormone+ cells, short exposure to hypergly-
caemia does not promote the desired differentiation outcome.
2.3 | Prolonged hyperglycaemia exposure 
hinders islet hormone expression
In contrast, the cells exposed to prolonged hyperglycaemia 
exhibited a marked decline of both the proportion of ins+-
cells (~−13%, 26.34%-13.04%) and glu+-cells (~−15%, 
33.57%-17.99%) (Figure 2F), however, displaying no signifi-
cant impact on the bihormonal cell fraction (Figure 2G). In 
addition, the number of NKX6.1+ and PDX+ cells, but not 
MAFA, was also significantly decreased (~−4.5%, 21.9%-
17.46% and ~−10%, 22.44%-11.96% respectively) when 
compared with the cells exposed for 4 weeks to a normogly-
caemic environment (Figure 2H). Consistently, the fraction 
of insulin cells coexpressing Pdx1+ declined by ~−8%, from 
23.36% to 15.46% (Figure 2I).
These results indicate that differentiation or maintenance 
of islet cell phenotypes is hindered by long exposure to a hy-
perglycaemic environment.
2.4 | Global proteomics 
revealed changes in the energy 
metabolism and redox homeostasis following 
short hyperglycaemia exposure
To thoroughly assess the hyperglycaemia effect on the trans-
planted cells differentiation outcome, we compared by global 
proteomics (using tandem mass tag [TMT] 10-plex proteom-
ics) the encapsulated cells retrieved from diabetic (D) and 
normoglycaemic mice (N), at either 1 or 4 weeks following 
xenotransplantation (Figures 3A and 4A). Only the proteins 
detected in at least one sample of each compared condition 
(2183 for 1w-postTX) were further considered. About one 
fifth (22.35%) represented differentially expressed proteins 
(DEPs) between the cells xenotransplanted for 1 week into 
diabetic mice (1w-postTX_(D)) and the ones introduced into 
normoglycaemic mice for an equivalent period of time (1w-
postTX_(N)) (Figure 3A, Table S2). To identify the canonical 
pathways, upstream regulators and protein networks defining 
this landscape, we performed pathway analysis on this DEP 
set using the Ingenuity Pathway Analysis (IPA) software.
The analysis identified pathways involved in oxidative 
phosphorylation (OXPHOS) and glucose metabolism in the 
top canonical pathways defining the set (Figure 3B, yellow 
and dark-green islands, Figure S2A). Based on their com-
ponents observed regulation these pathways were predicted 
as activated (Figure 3B table, Figure S2A), indicating an in-
creased energy metabolism of the hyperglycaemia-exposed 
cells, a regulation pattern suggestive of increased reactive 
oxygen species (ROS) production.22 In response to ROS 
overproduction the cells usually deploy detoxifying mecha-
nisms.23 Several pathways with known antioxidant protection 
function, such as NRF2-mediated Oxidative Stress Response 
(Figure 3B, orange border), were found amongst the top five 
activated pathways. Moreover, NF2L2 (NRF2), the major 
key regulator of antioxidant gene expression regulation, pro-
tecting against oxidative stress24 and NUPR1, a transcription 
regulator involved in cell cycle control that confers resistance 
to microenvironment changes stress, were predicted as the 
leading two activated transcription factors accountable for 
the observed proteome landscape regulation (Figure S2B).
These observations are consistent with hyperglycaemia expo-
sure increasing the glycolysis and consequently the respiratory 
activity and ROS production of the transplanted differentiating 
cells, which respond by activating key detox mechanisms.
Furthermore, several top pathways shared as common 
denominator the AKT2 signalling cascade (Figure 3B, light-
green island) (Figure S2A). In accordance with AKT2 ob-
served upregulation, regulatory hubs like RICTOR and 
ADORA2A were predicted as top upstream regulators (Figure 
S2C). Interestingly, the AKT-based signalling was linked to 
the energy metabolism pathways by our network analysis 
(Figure 3C). A large body of literature involved AKT2 either 
in a ROS-stimulated positive feedback loop, promoting the 
glucose flux or in ROS signalling transduction, facilitating 
diverse ROS-mediated changes in gene expression.25-28
Last, sectors of the observed proteome landscape reflected 
the inactivation of chromatin binders involved in differentiation 
regulation, such as the epigenetic modifier DNMT3B (methy-
lase) and the oestrogen receptor alpha inhibitors SAFB2 and 
SAFB, involved in cell cycle/differentiation modulation in re-
sponse to stress29 (Figure S2D). In contrast, SMARCA4, an 
ATP-dependent chromatin remodeler was predicted activated 
(Figure S2B). These data point at subtle epigenetic changes in 
gene expression as result of hyperglycaemia exposure.
Altogether, these results suggest that the response of the 
transplanted differentiating cells to short-term hypergly-
caemia revolves around actively attempting to maintain the 
redox homeostasis. Nevertheless, the inferred changes in the 
epigenetic landscape regulation suggest the tilting of balance 
towards ROS accumulation.
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2.5 | Brief hyperglycaemia exposure 
promotes proteins involved in redox balance
To investigate the impact of the hyperglycaemia exposure on 
islet cells signature, we focused on proteins normally found in 
bonafide islet cells. For this we compared by TMT 10-plex-
based quantitative proteomics the pancreatic progenitors 
transplanted for 1  week in diabetic/normoglycaemic mice 
and human islets isolated from apparently healthy cadaveric 
donors. Both the Principal Component Analysis plot (Figure 
3D) and hierarchical clustering (Figure S2E) displayed a 
clear separation of the conditions analysed. As expected, the 
transplanted cells conditions cluster close to each other and at 
distance from islets samples.
We then addressed the effect of hyperglycaemia on 
the proteins differentially expressed between normogly-
caemia-exposed transplanted samples and human islets. 
Briefly, 647 DEPs (FC ≥1.5, P < .05, Table S3) were fil-
tered between 1w-postTX_(N) and human islets samples, 
representing the difference in the proteome landscape be-
tween the standard (normoglycaemia differentiating pan-
creatic progenitors) and the bonafide islets cells. These 
were k-means clustered based on their islet-normalized 
regulation pattern following brief hyperglycaemia exposure 
(Figure 3D). Nine clusters were obtained, manually curated 
for errors and distributed into two classes according to their 
profile dynamic: (a) upregulated and (b) downregulated in 
response to hyperglycaemia.
The upregulated class represented one third of the total 
DEP set (~33% 211/647). The pathway analysis revealed 
that the energy metabolism pathways identified above are 
transduced by proteins belonging in this group (Figure 
3E, chartreuse islands, Figure S2F), with signalling cas-
cades performing an antioxidant function found in the top 
canonical pathways (orange islands, Figure 3E, Figure 
S2F) and predicted activated (table Figure 3E). This was 
further corroborated by the network analysis that identi-
fied upregulated SOD1 (superoxide dismutase), one of the 
two key antioxidant enzymes involved in destroying ROS 
in the body,30,31 as a node of a leading network defining 
the analysed proteome landscape (Figure 3F). Accordingly, 
NRF2 was predicted as the top activated upstream regula-
tor (Figure S2G).
In addition, the program inferred that proteins of this group 
are also involved in inflammation and actin cytoskeleton 
remodelling, two processes linked to oxidative stress32-34 
(Figure 3E, magenta, blue rectangles). Accordingly, NFkB, the 
lead molecule linking oxidative stress to inflammation,35-38 was 
predicted as centre of the lead network (Figure S2H), despite 
not being significantly regulated in the actual assay.
These results suggest that this class consists of proteins 
involved in redox balance regulation and inflammation in re-
sponse to hyperglycaemia.
2.6 | Proteins downregulated in response to 
brief-hyperglycaemia exposure are involved in 
protein synthesis and differentiation regulation
We subsequently focused on the proteins downregulated fol-
lowing the short-term exposure to hyperglycaemia. The analy-
sis of the resulted 129 DEPs revealed that most are involved in 
protein and amino acid metabolism (Figure S2I,J, Table S3). 
Moreover, JNK, NFkB and P38 MAPK, well-known ROS 
signalling transducers,24,39-43 were central nodes of a lead pro-
tein network (Figure S2K), further corroborating the potential 
involvement of NFkB in signal transduction in response to 
brief hyperglycaemia. Of note, the proteins used to infer the 
above-mentioned DNMT3b inactivation, resided in this class 
(Figure S2L). These results suggest that short hyperglycaemia 
exposure decreases the abundance of proteins involved in the 
epigenetic regulation of the transcriptional landscape, among 
others.
2.7 | Short-term hyperglycaemia exposure 
impedes the activity of specific epigenetic 
modifiers with key role in β-cells identity 
maintenance
To test a possible connection between the predicted de-
crease in methylase activity and the increased generation 
of bihormonal glu+ins+ cells observed 1 week after in vivo 
hyperglycaemia exposure (Figure 2A,C), we mined the data-
set for epigenetic modifiers described to play a role in islet 
endocrine cell fate decisions.44 We identified the significant 
downregulation of MECP2 (Figure 3G), an essential enzyme 
involved in maintaining and propagating the repression of 
α-cell fate in β-cells. This methyl-binding protein is recruited 
in β-cells to the methylated locus of the main α-cell lineage 
F I G U R E  3  Pathway analysis of the proteome landscape following short-term hyperglycaemia exposure. (A) Experimental design of 
the comparison analysed. (B) overlapping canonical pathways map and tables depicting the top canonical pathways predicted activated for the 
proteins differentially expressed between hyperglycaemia and normoglycaemia samples retrieved after 1 wk. (C) Selected top radial network 
centred on Akt. (D) PCA plot of the conditions analysed and analysis workflow depicting the k-means clustering and clusters selected in the 
upregulated proteins class. (E) Overlapping canonical pathways map and tables depicting the top canonical pathways predicted activated of the 
1-week hyperglycaemia-exposure upregulated protein class (F) Selected top radial network centred on SOD1. (G) Graph of the observed MECP2 
downregulation in short-term hyperglycaemia exposed samples. Data are shown as mean ± SD. PCA, Principal Component Analysis
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determinant gene Arx (aristaless-related homeobox), actively 
repressing its transcription and thus maintaining β-cell fate. 
ARX affects α-cell differentiation, but not directly glucagon 
gene transcription, nevertheless it has a critical role in sup-
pressing the β-cell phenotype. Loss of MECP2 in β-cells was 
shown to result in a steep increase in Arx expression, coupled 
with the decrease in the main β-cell markers PDX1, PAX4 
and Insulin, and the upregulation of key α-cell markers, such 
as Glucagon and MAFB.45
Unfortunately, because of the unavoidable sensitivity lim-
itation caused by performing proteomics on encapsulated 
cells, we were unable to detect proteins with very low abun-
dance, such as ARX, hence we could not confirm its upreg-
ulation following MECP2 loss. Moreover, to our knowledge 
there is no study describing the ARX target genes in the pan-
creatic islet, hence their activation could not be assessed.
Thus, to partially validate in a different setup the role of 
increased oxidative stress on the loss of cell identity and ARX 
regulation, we analysed Matrigel-cultured differentiated cells 
treated with Wnt5a, a previously reported inducer of oxida-
tive stress.46 This in vitro setup grants a much better coverage 
of the proteome, allowing mining for ARX expression.
The global proteome analysis of the DEPs between the 
treated and untreated cells confirmed an increase in the en-
ergy metabolism and antioxidant protection signatures (Figure 
S3A). Interestingly, the data mining of the set revealed the 
downregulation of MECP2 and the subsequent ARX upreg-
ulation (Figure S3B). Furthermore, there was a significant 
increase in the fraction of insulin+ cells also expressing glu-
cagon+ (bihormonal cells) in this context as compared to un-
treated control (from 24.29% to 43.23%, Figure S3C,D).
Globally, the above series of analyses advance a model in 
which short-term in vivo exposure to hyperglycaemia induces 
oxidative stress, caused by increased glucose flux, promoting 
increased OXPHOS and accumulation of ROS. Moreover, 
our data suggest that AKT2-mediated signalling pathways 
contribute to the oxidative stress response mechanism. The 
transplanted cells respond to the ROS overproduction by ac-
tivating detox mechanisms. Nevertheless, these seem to be 
inefficient in maintaining the redox balance as processes like 
inflammation, cytoskeleton remodelling and changes in the 
epigenetic landscape regulation (such as cells with mixed iden-
tity) were detected, probably transduced via the NFkB hub.
2.8 | Cells exposed in vivo to long-
term hyperglycaemia exhibit minimal 
antioxidant protection response to increased 
oxidative stress
When compared with brief hyperglycaemia exposure, sur-
prisingly fewer proteins (11.18%) were differentially ex-
pressed between the 4w-postTX_(D) and 4w-postTX_(N) 
samples. Moreover, only 54 DEPs were regulated by both 
hyperglycaemia exposures periods, representing 11.27% and 
16.27% of the respective DEP sets, suggesting that exposure 
length impacts differently the proteome landscape.
We further characterized the proteome changes in 
4w-postTX_(D) as compared to their control counterparts 
(4w-postTX_(N)) (Table S2). The analysis revealed in 
the top toxicity list (a) the Mitochondrial Disorder and (b) 
Increases Transmembrane Potential of Mitochondria and 
Mitochondrial Membrane. As for the short-term hypoglycae-
mia exposure, the strong activation of OXPHOS pathway was 
predicted with a high activation score, suggesting it as a com-
mon response to hyperglycaemia regardless of the exposure 
period (Figure 4B). Similar regulation patterns (activation) 
were also exhibited by AMPK signalling and Coagulation 
system pathway (Figure 4C).
Despite these similarities, the comparison identified sub-
stantial differences in the proteome fingerprint between the 
two contexts. A large group of pathways were predicted to 
display an absent or even an opposing pattern of regulation be-
tween the two hyperglycaemia exposure periods. Specifically, 
glucose metabolism (such as Glycolysis I, Gluconeogenesis I) 
and Antioxidant protection signalling (such as NRF2-mediated 
Oxidative Stress Response or Sirtuin Signalling), that govern 
the response to short-term hyperglycaemia were not predicted 
as regulated in this context (Figure 4D). Moreover, pathways 
like Insulin Receptor and ILK Signalling displayed opposing 
F I G U R E  4  Comparative pathway analysis of the proteome landscapes following brief and long-term hyperglycaemia exposure. (A) 
Experimental design of the comparison analysed. (B) Comparative analyses of the canonical pathways between hyperglycaemia exposed and 
normoglycaemia samples at 1w-postTX (left column) and 4w-postTX (right column, bordered) (C) the three pathways predicted activated in 
both conditions compared. (D) The canonical pathways predicted activated only in the samples exposed for short-term to hyperglycaemia as 
compared to normoglycaemic samples. (E) The canonical pathways exhibiting opposing activation patterns between the two conditions analysed. 
(F) Production of Nitric Oxide and ROS pathway contrasting activation status is predicted activated in the 4w-postTX condition. (G) CDK5 
Signalling predicted activation solely in the 4w-postTX condition. (H) Selected top IPA radial network centred on MAPT. (I) Comparative IPA 
activation predictions between the 1w-postTX and 4w-postTX upstream regulators. (J) IPA generated hierarchical clustering of the predicted 
disease and function processes for the conditions compared. Apoptosis and Fragmentation of Golgi apparatus exhibit different predicted activation 
pattern, with predicted activation in the 4w-postTX condition. (K) high magnification confocal images of apoptotic insulin+ cells in the long-term 
hyperglycaemia exposed samples illustrating apoptosis-specific nuclear fragmentation (arrowheads) and membrane blebbing (arrows) (scale bar: 
5 µm). (L) Quantification of apoptotic insulin+ cells (n = 9-11 bead confocal fields). IPA, Ingenuity Pathway Analysis; ROS, reactive oxygen 
species
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activation patterns, being predicted as inactivated in the long-
term condition (Figure 4E). Importantly, the sole pathway 
exhibiting an inactive-to-active between brief and prolonged 
hyperglycaemia exposure was Production of Nitric Oxide and 
ROS (Figure 4F), indicating changes in the proteome land-
scape caused by high generation of oxidants. In addition, 
CDK5 Signalling is one of only three entities to be predicted 
as activated exclusively as a result of extended hyperglycae-
mia exposure (Figure 4G). CDK5 Signalling is known to be 
active in β cells, inhibiting insulin exocytosis and thus reduc-
ing insulin secretion.47
Furthermore, the network analysis identified downregu-
lated MAPT (microtubule associate protein tau), as the main 
node of the Energy Production network of this proteome 
landscape (Figure 4H). Of relevance, this regulator was re-
cently correlated with mitochondrial hyperpolarization and 
oxidative stress in hiPSC-derived neurons from patients bear-
ing mutations in the Mapt gene.48
Several regulators shared similar activation profiles 
between the hyperglycaemia periods, such as SMARCA4 
and STK11 (Figure 4I). Nevertheless, as revealed also by 
the canonical pathways analysis, many were predicted to 
exhibit opposing regulations, thus disclosing radically dif-
ferent target proteome landscapes in response to the differ-
ent hyperglycaemia exposure periods. One of these, REL 
(mammalian NF-kB subunit), is a major player in regulat-
ing ROS amounts in the cell by increasing the expression 
of antioxidant proteins and protecting against oxidative 
damage. REL was predicted as activated following brief 
hyperglycaemia exposure, whereas the analysis of the long-
term effect revealed it as inactivated. Similarly, NF2L2 
(NFR2), the key antioxidant protection regulator, confi-
dently predicted as activated based on 1-week transplanted 
samples signature, could not be inferred as regulated based 
on 4-week proteome landscape. In contrast, WT1, levels 
were directly correlated with oxidative stress by previous 
research49 was predicted activated following long- but not 
short-term hyperglycaemia exposure.
Moreover, the comparative diseases and functions anal-
ysis also confirmed a cohort of processes displaying oppo-
site regulation. Active cell proliferation and cell survival on 
a background of inflammatory processes characterized the 
short-term hyperglyacemia exposure landscape, whereas the 
long-term exposure seemed to be defined by low inflamma-
tion, cell cycle inhibition and increased apoptosis (Figure 4J). 
Indeed, a brief high resolution assessment of the retrieved 
encapsulated cells 4w-postTX_(D) hyperglycaemic expo-
sure revealed that at this stage significantly more insulin+ 
cells displayed typical signs of apoptosis, such as apoptotic 
blebbing and nuclei fragmentation, which were not present 
in 4w-postTX_(N) normoglycaemic samples (Figure 4K,L).
Thus, based on the above series of analyses, a model 
can be proposed where prolonged in vivo exposure to 
hyperglycaemia will overcome the antioxidative protection of 
the cells, leading to increased ROS accumulation. Excessive 
ROS will promote apoptotic cell death in susceptible cells.
3 |  DISCUSSION
To the best of our knowledge, this is the first study re-
porting the in vivo impact of hyperglycaemia on the islet 
cell fate acquisition and identity of xenotransplanted 
human pancreatic progenitors. Although hyperglycaemia 
increased the oxidative stress signature regardless of expo-
sure period, the cellular and proteome landscape response 
to the ROS overproduction was different, relying on largely 
distinct mechanisms according to the period spent in the 
hyperglycaemic environment. Brief hyperglycaemia expo-
sure increased the bihormonal cell number and activated 
antioxidant protection mechanisms, whereas prolonged 
exposure was characterized by decreased hormone+ cells, 
low/absent detoxification signature, activation of oxidative 
stress pathways (Production of Nitric Oxide and ROS) and 
increased apoptosis.
We believe we are the first to report xenotransplantation 
of differentiating hiPSC-derived cells into the RIP-DTR NSG 
mouse model. Using this approach we eliminated many of 
the variables inherently occurring when employing classical 
chemical models of β-cells destruction, which are charac-
terized by high individual variations in β-cell ablation effi-
ciency, inefficient ablation or overall toxicity issues, such as 
renal failure.
Of note, this study was strictly focused on characterizing 
the global proteome landscape changes in response to in vivo 
hyperglycaemia exposure, limited to the period immediately 
following the transplant. Consequently, it provides only a 
broad picture of the molecular events governing this process. 
Undoubtedly, the complex network of regulation uncovered 
needs further experimental dissection and validation in future 
studies.
Although a totally new finding in regard to transplanted 
hiPSC-derived pancreatic progenitor cells differentiat-
ing towards islet cell fates, the ability of hyperglycaemia 
to drive ROS overproduction was previously described 
in other contexts.42,50,51 These studies showed that hyper-
glycaemia is increasing the glucose flux and TCA cycle 
(Krebs cycle), consequently raising the levels of electron 
transfer donors (NADH, FADH2) that, in turn, enhance 
OXPHOS and ROS production.23,52,53 Our analysis was 
consistent with this scenario revealing a pattern of regula-
tion reflecting the consistent activation of both Glycolysis 
and OXPHOS in the top activated pathways, regardless of 
the hyperglycaemia exposure period. Moreover, the TCA 
cycle activation was further inferred in the prolonged ex-
posure samples.
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Several studies proposed hyperglycaemia-induced oxi-
dative stress as a main driver for multiple diabetes compli-
cations.54-57 Our results contribute to this list, by exposing 
the harmful effect of hyperglycaemia exposure on islet cell 
fate acquisition. This is especially relevant in the context 
of future hiPSC-based therapies for diabetes, as it high-
lights the importance of patient glycaemia control, espe-
cially during the initial period following the transplant. 
Of course, we cannot exclude that further matured islet 
cells might cope better with sustained hyperglycaemia ex-
posure, nevertheless in the light of increasing amount of 
studies linking hyperglycaemia to oxidative stress in ma-
ture cell types, it is expected that they will also be affected. 
Interestingly, a previous study based on the transplantation 
of mouse bonafide pancreatic islets (mature islet cells) un-
derneath the kidney capsule of streptozocin-induced hy-
perglycaemic mice with or without insulin treatment also 
supports this hypothesis.58 Despite employing a different 
experimental setup, the authors observed that transplanted 
islets exposed to hyperglycaemia showed increased β-cell 
mass 10-days after transplant, followed by a decrease at 
30-days becasue of β-cell apoptosis. These results are 
comparable with our observations, suggesting that finally 
matured cells are also negatively affected by long-term hy-
perglycaemia. Nevertheless, it should be considered that 
parameters such as the difference in oxygen exposures 
between cells in suspension and bonafide islets as well as 
distinct transplantation sites are expected to influence the 
raw readouts between the studies. Of note, the authors also 
observed a steep decrease in the β-cell numbers 3-days fol-
lowing transplantation regardless of glycaemia condition,58 
suggesting that the decrease in the islet cell numbers is a 
result of the transplant (necrosis) and not hyperglycaemia.
In addition, we observed the downregulation of MECP2 
methyl-binding protein, a critical repressor of α-cell fate 
in β-cells.45 This provides a potential explanation for the 
increase in bihormonal cells expressing both glucagon and 
insulin. To our knowledge, this is the first study propos-
ing a link connecting increased hyperglycaemia-induced 
oxidative stress and the loss in cell identity manifested by 
occurrence of bihormonal cell entities. If proven true by fu-
ture studies, this will have important repercussions for the 
interpretation of the origin of bihormonal cells in human 
diabetic patients.59,60
Finally, we propose a working model in which the trans-
planted cells activate antioxidant protection mechanisms 
to cope with hyperglycaemia-induced ROS production. 
However, sustained hyperglycaemia exposure will in time 
exceed these mechanisms, causing ROS accumulation, 
leading to altered proteome signatures and impacting islet 
cell fate acquisition. When further prolonged, ROS over-
production will lead to increased cellular damage and cell 
death.61-63
4 |  MATERIALS AND METHODS
4.1 | Cells and mice sources
The Norwegian Regional Committee of Medical and Health 
Research Ethics approved the reported experimental proto-
cols used for hiPSCs (REK 2010/2295) and for human islets 
(REK 2011/426). All methods were carried out in accord-
ance with the Helsinki Declaration. Informed consent was 
obtained from the healthy donor (skin fibroblasts) or from the 
relatives (organ donations). We used hiPSC line previously 
generated via episomal reprogramming from skin fibroblasts 
collected from a healthy donor.5 Human islets were obtained 
as previously described,64 here from eight donors, men and 
women between 41 and 63  years old (Table S1). Briefly, 
human pancreas were obtained from brain-dead donors, and 
digested by collagenase solution, and islets were separated by 
a Ficoll gradient. In this study, one of the human islet samples 
was excluded because of technical issues. We used the fol-
lowing transgenic mouse line NOD Cg-PrkdcscidIl2rgtm1Wjl 
Tg(Ins2-HBEGF)6832Ugfm/Sz mice,65 referred to as NSG 
RIP-DTR mice. All animal procedures were performed in 
accordance with the EU Directive 2010/63/EU for animal 
experiments. The breeding strategy and experimental pro-
tocols were approved by The Norwegian Animal Research 
Authority (FOTS ID 8329 and 8423).
4.2 | In vitro differentiation
The hiPSCs line (passage >20) was characterized and con-
firmed to have normal karyotype and tested negative for my-
coplasma on MycoAlert Mycoplasm Detection Kit (Lonza, 
LT07-418). The hiPSC line was enriched for SSEA4+ cells 
using magnetic beads (cat.#130097855 MACS Miltenyi 
Biotec) before in vitro differentiation. Two million hiPS 
cells per condition were differentiated following a seven-
stage differentiation protocol9 in planar culture conditions 
on Matrigel-coated plates up to stage S5 (pancreatic endo-
crine precursors), which involves adding different mixtures 
of chemicals to mimic the stages of mouse pancreatic devel-
opment for a duration of 2 weeks as described previously.5
4.3 | Alginate encapsulation
S5 cells were collected using TrypLE Select Enzyme 
(cat.#12563011, Thermo Fisher), after viability check and 
counting on NucleoCounter NC-200, were resuspended in 
MCDB131 medium and mixed to a total concentration of 
1.8% alginate in 0.3 mol/L mannitol. We used ultra-pure LVG 
(70% G and 198 mPas) sodium alginate (batch #BP-0907-02, 
FMC BioPolymer AS NovaMatrix). Gel beads were created 
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using an electrostatic bead machine (Nisco Engineering AG) 
having a potential difference of 7 kV at a flow of 50 mL/h, 
with a standard nozzle with flat cut tip with an inner diam-
eter of 0.5 mm. Alginate beads were incubated for less than 
10 minutes in gelling solution (50 mmol/L CaCl2, 1 mmol/L 
BaCl2 in 0.15 mol/L mannitol, 10 mmol/L HEPES, pH 7.2),20 
and rinsed three times in MCDB131 medium.
4.4 | Transplantation
Males RIP-DTR NSG mice (8-12  weeks old) were sepa-
rated into two groups, six mice per group. The mice were 
housed in individually ventilated cages enriched with 
wooden bedding, nesting material, in a temperature-con-
trolled environment at 22°C under a 12-h light-dark cycle. 
The mice were given ad libitum access to water and stand-
ard diet RM1A (SDS). First group received three intraperi-
toneally (ip) DT (Sigma, cat.# D0564-1MG) injections to 
induce diabetes as previously described.18,19 Blood glucose 
was monitored twice a week at 4-5 pm with a Contour XT 
glucometer (Bayer) to confirm diabetes (blood glucose 
>300  mg/dL on 2 consecutive measurements). Diabetic 
mice received an insulin implant (Linbit) 5 days after DT 
injections to ensure survival. The diabetic mice remained 
hyperglycaemic after implant. Each diabetic and normo-
glycaemic mouse received intraperitoneally alginate beads 
containing in total 5 million pancreatic progenitor cells 
differentiated in vitro. For transplantation, the mice were 
anesthetized using inhalable sevoflurane administered via 
Datex-Ohmeda Sevotec 5. Transplanted mice were given 
0.5  mg/mL paracetamol in the drinking water for 5  days 
after transplantation. After 1 or 4  weeks, blood was col-
lected from the tail and the mice were killed by cervical 
dislocation and the alginate beads were collected from the 
intra peritoneal cavity and prepared for either immunoflu-
orescence or proteomics analyses. Three mice from each 
group were analysed at each timepoint. The pancreas was 
also collected and processed for immunofluorescence.
4.5 | Human insulin measurement
Blood from the mice were collected in Lithium Heparin tubes 
and centrifuged at 14 000 g for 10 minutes, and plasma were 
collected. Human insulin quantities were measured using the 
Mercodia Ultrasensitive Insulin ELISA (10-1132-01, Mercodia).
4.6 | Immunofluorescence staining
Alginate beads were fixed in 4% paraformaldehyde for 1 hour 
at room temperature and stored in PBS at 4°C until use. The 
NSG RIPDTR pancreas was fixed in 4% PFA for 2 hours at 
RT, then dehydrated in a sucrose gradient of 10, 20, 30% su-
crose and embedded in Tissue Tek OCT compound (Sakura 
JP). 10 μm sections were obtained using a cryotome (Leica 
CM 1950, Leica, DE) and added on SuperFrost® Plus slides 
(Thermo Scientific). The immunofluorescence staining was 
performed conformed indications provided by the supplier. The 
following primary antibodies were used: mouse anti-insulin 
IgG1 (1/500, I2018, Sigma-Aldrich), guinea-pig anti-porcine 
insulin (1/400, A056401-2, Dako), mouse anti-porcine gluca-
gon (1/1000, G2654, Sigma-Aldrich), guinea-pig anti-PDX1 
(1/500, ab47308, Abcam), rabbit anti-NKX6.1 (1/100, NBP1-
82553, Novus), rabbit anti-MAFA (1/200, ab98859, Abcam) 
and rabbit anti-NEUROD1 (1/200, ab16508, Abcam). The fol-
lowing secondary antibodies were used at dilution 1/500: goat 
anti-mouse IgG1 A488, goat anti-guinea-pig A488, goat anti-
mouse IgG1 A647, goat anti-guinea-pig A546, donkey anti-
rabbit A647 and donkey anti-rabbit A647 (Molecular Probes). 
DAPI (1/1000, D1306, Molecular Probes) was used to stain 
the nuclei. The samples were mounted in Prolong Diamond 
Antifade Mountant Media (P36970, Life technologies). Image 
acquisition was performed on Andor Dragonfly confocal mi-
croscope. Antibody validations: endocrine markers were tested 
on different tissues, for example mouse pancreas cryosections, 
transplanted and in vitro hiPS-derived differentiating hormone 
expressing cells. A known positive slide of pancreatic tissue 
was used for staining validation.
4.7 | Confocal Imaging
Whole mount beads were imaged using the Andor Dragonfly 
5050 (Andor Technologies, Inc) confocal microscope with 
20x dry objective (CFI Plan Apochromat Lambda 20x). 
Each bead was imaged with 3 × 3 FoV, which covered the 
entire bead. The z-stacks were acquired from the top of 
each bead, and 100 steps of 4 μm with a total of 400 μm 
depth, which corresponded to the imaging depth. Each 
image was taken with high-speed iXon 888 Life EMCCD 
camera with 1024 × 1024 resolution. For nuclear imaging 
we used 405 nm laser with intensity of 30%-50% and an 
exposure time of 40-100 ms For detecting proteins, laser 
488, 546 and 647 were used with laser intensity ranging 
from 5%-30% and exposure time of 30-50, depending on 
the antibody and sample. High magnification images were 
acquired on Leica TCS SP5 confocal (Leica Microsystems 
CMS GmbH).
4.8 | Automated cell counting
Imaris 9.1.2. (Bitplane AG) was used to analyse the im-
munofluorescence pictures. For counting each bead was 
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considered one unit. A surface mask was used on the DAPI 
signal, with filters on absolute intensity from 600 or 1200 
to max, quality minimum between 30 and 100 and size be-
tween 100 μm and 10 000 μm with separation of nuclei in 
clusters of 8 μm in diameter. For the different proteins spot 
masking was used with quality minimum ranging from 30 
to 1500 depending on antibody and intensity of staining. 
The same settings were used for all beads of same stain-
ing from the same mouse. The MatLab plugin ‘Find spots 
close to surface’ within 1  μm was used to analyse only 
spots belonging to a nucleus, which removed the unspe-
cific staining from the analysis. The MatLab plugin ‘Find 
colocalizing spots’ within 1  μm was used to identify the 
cells co-expressing two proteins.
4.9 | Global proteomics analysis
Encapsulated cells were lysed directly in the alginate 
beads, in a buffer containing 8 mol/L Urea, 200 mmol/L 
EPPS pH8.5 and protease inhibitors (Roche complete 
with EDTA) and sonicated (30 seconds × 3 times at 30% 
power). Human islets were processed as previously de-
scribed,5,14 is short by boiling in 4% SDS buffer before 
sonication. Chloroform-Methanol precipitation was per-
formed on alginate beads as previously described,66 in-
volving adding methanol, chloroform and water before 
centrifugation thereafter the alginate were removed as best 
as possible. All peptides were desalted and dried. Protein 
processing and TMT 11-plex labelling was performed as 
described previously5,14 apart from halved volume of TMT 
reagents. In short, the desalted peptides were re-suspended 
in 200 mmol/L HEPES before addition of CAN and TMT 
reagents for 1.5 hours before quenching of the reaction by 
5% hydroxylamine. TMT-labelled samples were combined, 
concentrated to near dryness and desalted with C18 solid 
phase extraction. We fractionated the pooled TMT-labelled 
peptide sample using the Pierce High pH Reversed-Phase 
Peptide Fractionation Kit (cat. # 84868). Twelve fractions 
were collected using: 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 
22.5%, 25%, 27.5%, 30%, 35% and 60% acetonitrile. Every 
sixth fraction was combined to yield a total of 6 fractions. 
Samples were subsequently acidified with 1% formic acid 
and vacuum centrifuged to near dryness. Each fraction was 
desalted via StageTip, dried again via vacuum centrifuga-
tion and reconstituted for liquid chromatography (LC)-MS/
MS processing.
4.10 | LC-MS3 analysis
From each of the six fractions, ∼5 μg was dissolved in 15% 
aqueous formic acid/5% acetonitrile prior to LC-MS/MS 
analysis on an Orbitrap Fusion Lumos mass spectrometer 
(Thermo Fisher Scientific) coupled to a Proxeon EASY-nLC 
1200 LC pump (Thermo Fisher Scientific). Peptides were 
fractionated on a 100-μm inner diameter microcapillary col-
umn packed with ∼35 cm of Accucore resin (2.6 μm, 150 Å, 
ThermoFisher Scientific). For each analysis, we loaded ~1 μg 
onto the column. Subsequent separation and acquisition were 
performed as previously described.5,14 Samples were analysed 
in duplicate, one with advanced peak determination (ADP) acti-
vated and a second run with this option off. Both analyses used 
the real-time search algorithm.67 Data were searched against the 
UniProt human database (downloaded: October, 2016).
4.11 | Data analysis
The mass spectrometry data were analysed as previously de-
scribed.5,14 Briefly, the mass spectra were processed using a 
Sequest-based in-house software pipeline,66 database search-
ing from the human Uniprot database, linear discriminant 
analysis for peptide-spectrum matches, before summing re-
porter ion counts to quantify proteins. Protein profiles from 
each mouse or human islet were treated as one unit. Protein 
quantitation values were exported for further analysis in 
Microsoft Excel and GraphPad Prism (version 8). The data-
set was uploaded to ProteomeXchange via the PRIDE (http://
www.prote omexc hange.org) partner repository with the 
dataset identifier PXD015071.
The hierarchical clustering was performed with 
GeneSpring 14.9.1 GX software (Agilent), with clustering 
on both entities and conditions using Squared Euclidian 
distance metric and Ward's linkage rule. The same program 
was used to generate 9 and 12 k-mean clusters for the 1 W 
and 4 W time points respectively. Clusters 0 and for 1 W 
and 0, 5 and 8 for 4 W were manually curated. The path-
way analyses were generated by QIAGEN’s IPA program 
(IPA®, QIAGEN, www.qiagen.com/ingen uity)68 as previ-
ously described,5,14 here using 35 molecules/network; 25 
networks/analysis for generating the interaction networks.
4.11.1 | RNA extraction and sequencing
RNA was purified from stage 5 cells (S5-cells) and human 
islets using the Qiagen RNeasy Micro Kit (ID74004, 
Qiagen, DE). The amount and quality of the purified RNA 
was measured using a NanodropOne (Thermo Scientific), 
before the samples were frozen and shipped to Qiagen 
Next-Generation Sequencing Center for sample sequenc-
ing and analysis. Second quality control, library prepara-
tion, sequencing, mapping and analysis up to normalized 
counts files were done at Qiagen Genomic Facility. We 
mined the normalized (fpkm) datasets for Neurod1 and 
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Neurog3 expression levels; the full datasets were deposited 
to the NCBI Gene Expression Omnibus repository, acces-
sion number GSE141309.
4.12 | Wnt5a treatments
In vitro differentiated cells were stimulated with Wnt5a 
(645-WN, R&D Systems) (400 ng/mL) for 4 hours and fur-
ther cultured for 48 hours in differentiation media before 
sample collection. Wnt5A-stimulated cells and non-treated 
controls were washed in DPBS 1x and incubated with 
TrypLE™ Select Enzyme (1X) (cat.#12563011, Thermo 
Fisher Scientific) for 5 minutes at 37°C, followed by cen-
trifugation (250  g for 5  minutes). Cell pellets were pro-
cessed for proteomics as described above. The raw mass 
spectrometry proteomics data containing these samples 
were deposited to the ProteomeXchange Consortium via 
the PRIDE partner repository with the dataset identifier 
PXD012081.
4.13 | Statistical analysis
The group assignment of the host mice was randomized. 
Because of the difference in glycaemia the groups could 
not be blinded during the collection of the blood glucose or 
weight measurements. Data are expressed as mean ± SD un-
less otherwise specified. Statistical analysis on the proteom-
ics data was tested using unpaired two-tailed Student's t test 
and a P-value of ≤.05 was considered significant. Two-way 
ANOVA with Tukey's multiple comparisons test were used 
to compare between the groups for number of cells positive 
for the different markers by IF staining. This analysis was 
performed using GraphPad Prism v8.1.2.
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